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Background: After initial treatment of differentiated thyroid carcinoma (DTC) patients are followed with
thyroglobulin (Tg) measurements to detect recurrences. In case of elevated levels of Tg and negative neck
ultrasonography, patients are treated 'blindly' with Iodine-131 (131I). However, in up to 50% of patients, the post-
therapy scan reveals no 131I-targeting of tumor lesions. Such patients derive no benefit from the blind therapy but
are exposed to its toxicity. Alternatively, iodine-124 (124I) Positron Emission Tomography/Computed Tomography
(PET/CT) has become available to visualize DTC lesions and without toxicity. In addition to this, 18F-fluorodeoxyglucose
(18F-FDG) PET/CT detects the recurrent DTC phenotype, which lost the capacity to accumulate iodine. Taken together,
the combination of 124I and 18F-FDG PET/CT has potential to stratify patients for treatment with 131I.
Methods/Design: In a multicenter prospective observational cohort study the hypothesis that the combination of 124I
and 18F-FDG PET/CT can avoid futile 131I treatments in patients planned for ‘blind’ therapy with 131I, is tested.
One hundred patients planned for 131I undergo both 124I and 18F-FDG PET/CT after rhTSH stimulation. Independent of
the outcome of the scans, all patients will subsequently receive, after thyroid hormone withdrawal, the 131I therapy.
The post 131I therapeutic scintigraphy is compared with the outcome of the 124I and 18F-FDG PET/CT in order to
evaluate the diagnostic value of the combined PET modalities.
This study primary aims to reduce the number of futile 131I therapies. Secondary aims are the nationwide introduction
of 124I PET/CT by a quality assurance and quality control (QA/QC) program, to correlate imaging outcome with
histopathological features, to compare 124I PET/CT after rhTSH and after withdrawal of thyroid hormone, and to
compare 124I and 131I dosimetry.
Discussion: This study aims to evaluate the potential value of the combination of 124I and 18F-FDG PET/CT in the
prevention of futile 131I therapies in patients with biochemically suspected recurrence of DTC. To our best knowledge
no studies addressed this in a prospective cohort of patients. This is of great clinical importance as a futile 131I is a
costly treatment associated with morbidity and therefore should be restricted to those likely to benefit from this
treatment.
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Keywords: Thyroid cancer, Recurrence, 124I, 18F-FDG, PET/CT, Cross-calibration, Thyropet* Correspondence: j.kist@nki.nl
1Department of Nuclear Medicine, The Netherlands Cancer Institute,
Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2014 Kist et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kist et al. BMC Cancer 2014, 14:405 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/405Background
Differentiated thyroid cancer (DTC) is the most frequent
endocrine tumor, with an annual incidence per 100.000
individuals of 1 – 3 in men and 2 – 4 in women [1]. In
general, DTC has an excellent prognosis, and only 5 to
10% will die of their disease [2,3]. Prognosis is less favor-
able when the disease recurs after primary treatment.
Local or regional recurrence occurs in 5 – 20% of patients
[4]. Distant metastases develop in up to 10%, usually in
the lungs and bones [5]. Recurrences are usually detected
during the early years of follow-up, but may occur years
later [6]. As in many diseases, early detection of recur-
rence improves outcome and survival, because limited dis-
ease load may allow surgical resection and/or effective
treatment with radioactive iodine (131I). Follow-up is
therefore necessary throughout the patients’ life. There-
fore, even though DTC incidence is low, many patients
are currently under surveillance for a possible recurrence
(estimated 500.000 in the United States) [7,8].
The serum marker Thyroglobulin (Tg) plays a pivotal
role in the follow-up of differentiated thyroid cancer.
Serum Tg should be undetectable in DTC patients follow-
ing effective thyroid remnant ablation with 131I, so that
any detectable level reflects (neoplastic) thyroid tissue [9].
The level of serum Tg is related to the amount of neoplas-
tic thyroid tissue; it has been estimated that 1 g of neoplas-
tic thyroid tissue corresponds with a serum Tg of 1 ng/ml
during thyroid hormone replacement therapy, and with
2 – 10 ng/ml following recombinant human thyroid
hormone stimulating hormone (rhTSH) stimulation
[10,11]. A serum Tg cut-off level ≥ 2 ng/ml following rhTSH
is highly sensitive to identify patients in whom persistent
tumor may be found with imaging techniques [12,13].
When recurrent DTC is suspected because of serum
Tg above the cut-off level, several imaging tests may be
performed to detect the exact sites of recurrence. The
sodium/iodide symporter (NIS) mediates iodide uptake
in the thyroid gland and thyroid cancer cells [14]. The
ability of the thyroid to accumulate Iodide via NIS is the
basis for scintigraphic thyroid imaging with radioiodine
(using the gamma-emitting 123I) as well as for therapy
using the beta-emitter 131I, which targets and destroys
iodide-transporting benign and malignant thyroid cells.
In thyroid cancer, the primary therapy is total thyroidec-
tomy, which in practice is near-total to spare adjacent
nerves and parathyroids. Postoperatively, 131I is used to
ablate these postoperative thyroid remnants, and to de-
tect (using post 131I whole body scintigraphy) and treat
potential metastases [15-17]. With this approach, highly
selective radiation doses can be achieved in tumor tissue,
often much higher than with external radiotherapy.
Historically, the follow-up of patients with DTC in-
cluded scintigraphy after a low activity of 131I if serum Tg
was elevated, but this is no longer recommended becauseof poor sensitivity [18-23]. To date, whole body scintig-
raphy after ‘blind’ administration of high ‘therapeutic’
activity of 131I is performed in these patients, during
withdrawal of thyroid hormone replacement to stimulate
uptake of iodine in cells of thyroidal origin, both to diag-
nose and re-stage the potential recurrence and to initiate
its treatment [18,24-28]. This strategy can be effective, but
an estimated 38% - 50% of patients will have a negative
post-therapeutic 131I whole body scan and/or no objective
therapy effect [29,30]. Such patients will have received a
total body irradiation of 450 millisievert (mSv) and may
have suffered from side effects such as nausea, sialoadeni-
tis, loss of taste, or reduced spermatogenesis. Further-
more, their risk of secondary malignancies has increased
[31,32]. All induced by a treatment from which they de-
rived no benefit. Also, the prolonged thyroid hormone
withdrawal and subsequent hypothyroidism necessary for
131I therapy have major impact on quality of life, with a
majority of patients suffering from significant changes in
physical, psychological, and social well-being [33-37]. The
high frequency of high activities 131I from which patients
do not derive any benefit but are exposed to its toxicity
and potential adverse oncological effects, has led to a
search for new diagnostic tools to improve the selection of
patients for such treatment.
Nowadays, ultrasound of the neck is applied to detect
a local recurrence or regional lymph node metastases
allowing direct biopsy to confirm the diagnosis. None-
theless, ultrasound is limited to the neck only, and when
negative in the presence of detectable Tg, whole body
evaluation is required.
Recently, Iodine-124 (124I) has become available as a
novel radionuclide for whole body Positron Emission
Tomography/Computed Tomography (PET/CT) in the
follow-up of DTC [38-41], with a promising diagnostic
accuracy and a considerably lower radiation exposure
than whole body scintigraphy after therapeutic activity
of 131I [39]. Furthermore, recent experience has shown
that 124I PET/CT images may be representative for the
biodistribution and radiation dosimetry of subsequent
therapy with 131I [42,43]. Thus, 124I PET/CT may allow
for more accurate restaging of patients in a whole body
procedure, perform dosimetry for subsequent 131I ther-
apy and predict the outcome of the treatment. However,
some recurrent DTC lesions do not accumulate iodine,
which is correlated with tumor dedifferentiation and this
implies a poor prognosis [5]. Patients suspected of non-
iodine accumulating DTC, so far only evident after futile
blind 131I therapy, require restaging before local or systemic
therapy may be applied. Metabolic PET imaging with the
glucose analogon 18F-fluorodeoxyglucose (18F-FDG), espe-
cially during (rh)TSH stimulation, has a high sensitivity to
detect recurrent DTC in patients with detectable Tg and
negative iodine scintigraphy [44]. It may correlate with a
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and can help to select patients for other treatment modal-
ities (surgery, external beam radiotherapy or multikinase
inhibitors [46-48]). 18F-FDG PET/CT is currently applied
only when prior treatment and imaging with therapeutic
activity of 131I has proven to be ineffective [49]. The value
of 18F-FDG PET/CT before 131I treatment has not been
tested.
At the biological level, 124I and 18F-FDG uptake is re-
lated to expression of the sodium iodine symporter (NIS)
[16], while 18F-FDG uptake is related to hexokinase-I
(HKI) and Hypoxia-inducible factor 1-alpha (HIF-1α) ac-
tivity [50,51]. The evaluation of the relation of 124I and
18F-FDG PET/CT imaging findings and histopathological
parameters (such as thyroglobulin, TTF1, Ki-67 and
Cytokeratine-19 staining) and response to 131I treatment
will give more insight in the fundamental knowledge
about DTC.
The present study aims to test the power of combined
for detect and characterize DTC lesions in patients with
suspected recurrence. Based on the characteristics of
124I and 18F-FDG PET/CT, it is reasonable to assume
that a combined strategy of imaging and histopatho-
logical evaluation at the time of suspected recurrence
will yield adequate information on the disease stage
prior to treatment with 131I, regardless of tumor dedif-
ferentiation, with a potential impact on clinical decision
making. The combination of both entities has been
suggested in proof of concept studies [52], illustrated
in Figure 1, but needs proper testing, to increase fun-
damental knowledge about DTC and further improve
treatment.
The multicenter design of this study requires highly
standardized procedures for 124I PET/CT. PreviouslyFigure 1 Images from two different patients scanned with both
124I and 18F-FDG PET/CT. The 124I PET/CT of patient 1 (a) shows
multiple 124I negative pulmonary nodules, which are evidently 18F-FDG
positive (b). The thoracic wall lesion of patient 2 is clearly 124I avid (c)
and showing no uptake on the 18F-FDG PET/CT (d).nationwide standardization was done for 18F-FDG PET/
CT in the Netherlands, which eventually evolved into
the European EARL accreditation system [53,54]. In
order to compare the scans between centers calibration
and standardization of the 124I PET/CT scans prior to
the start of the study will be done a in quality assurance
and quality control (QA/QC) program.
In summary, therapy with high activities of 131I for re-
current DTC is effective in many cases, but the current
blind approach also leads to overtreatment, delay, and un-
necessary decrease in quality of life in a significant num-
ber of cases. As we described, a combination of diagnostic
tests has a potential to allow earlier and better restaging
and selection for treatment. The proposed trial aims to
test the value and optimal implementation of these new
tests, standalone and in combination, to derive parameters
for a new personalized strategy for diagnosis and treat-
ment of patients with (suspected) recurrent DTC.
Methods and design
Study objectives
The primary aim of the study is to evaluate the value of
combined imaging with 124I and 18F-FDG PET/CT in
the prevention of futile treatment with high therapeutic
activity of 131I. Interpretation of both PET-scans will
lead to a positive or negative treatment proposal. This
will be compared with the actual response on therapy.
The definition of a futile treatment will be a negative
post blind 131I therapy scintigraphy.
We define four secondary aims. Firstly, our aim is to
organize a synchronized introduction and QA/QC of
124I PET/CT in the Netherlands. More specifically, we
aimed to create a procedure for the cross-calibration of
124I PET/CT in a multicenter setting, which guarantees
reliable and comparable quantification, and is practical
to use. The procedure should result in calibration factors
per scanner and an indication of a measurement threshold
of the scanner, which is defined as the lowest activity that
can be reliably quantified. The measurement threshold
will be determined per vendor.
Secondly, translational correlation of 124I and 18F-FDG
PET/CT with histopathology (where available) and
treatment outcome will be done, in an explorative set-
ting. The outcome of the treatment is defined as a posi-
tive or negative post-therapy scan. This scan and both
124I and 18F-FDG PET/CT will be correlated with histo-
pathological features. The expression of different markers
will be quantified in the samples. In this way we aim to de-
termine which histopathological features of both primary
tumor and metastatic lesions can predict outcome of the
scans.
Thirdly, the study aims to investigate whether 124I PET/CT
has the same diagnostic, dosimetric and prognostic
yield during stimulation with rhTSH as with hormone
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PET/CT will be performed both after stimulation with
rhTSH and after withdrawal from levothyroxine it is pos-
sible to determine any differences in outcome from the
two scan preparation strategies. Both visual assessment as
the quantifiable data will be compared. As simultaneous
administration of 131I and 124I is required this can only be
done in selected.
Fourthly, we aim to compare 124I PET/CT and 131I scin-
tigraphy dosimetry and correlate the results with clinical
outcome. As 124I PET cannot be considered as the golden
standard for dosimetry of iodine therapy the dosimetry
based on 124I PET will be compared with 131I-scintigraphy
dosimetry. An additional phantom study will be per-
formed to correlate the results.
Study design
This study is designed as a nationwide multicenter obser-
vational cohort study. The study population includes pa-
tients with biochemically suspicion (i.e. increase Tg levels)
of recurrence of their previously completely removed thy-
roid carcinoma without evidence of local recurrence,
planned for ‘blind’ therapeutic activity of 131I.
The patients to be included in the study should meet
the following inclusion criteria:
1. Patients with a history of differentiated thyroid cancer
2. After complete thyroidectomy and ablation of
functional remnants with 131I.
3. Planned for ‘blind’ treatment with high activity of
131I based on biochemically suspected recurrence,
defined as a Tg-level above 2.0 ng/ml.
4. Ultrasonography of the neck performed < 2 months
prior to inclusion.
If one of the following criteria is met patients will be
excluded from the study:
1. Age < 18 years
2. Pregnancy
3. Incapacitated subjectsFigure 2 Flow chart THYROPET study. †Only in selected centers; if allow
center; # 124I and 18F-FDG PET/CT only if pre-therapy scan was positive.4. Contrast enhanced CT performed < 4 months prior
to inclusion
5. 131I therapy performed < 12 months prior to
inclusion
6. Indication for other therapy modality (i.e. surgery in
case of a positive ultrasonography, radiotherapy,
embolization or chemotherapy)
Study endpoints
Primary endpoint is the number of futile high dose 131I treat-
ments that could have been avoided by implementation of
pre-therapy imaging based on post-therapy scintigraphy
Four secondary endpoints were defined: (1) Synchro-
nized QA/QC of 124I PET in the Netherlands, (2) cor-
relation of 124I PET/CT and 18F-FDG PET/CT with
histopathological parameters, (3) correlation between
124I PET/CT findings during rhTSH and withdrawal
combined with low-iodine diet and (4) correlation between
124I PET/CT and 131I-scintigraphy dosimetry.
Study procedures
The study consists of four phases: pre-therapy, between
pre-therapy and therapy, therapy and follow-up phase.
For each phase the main study procedures are described
below. Figure 2 shows an overview of the most important
procedures.
Pre-therapy phase
Patients with biochemically confirmed recurrent DTC,
will undergo 18F-FDG and 124I PET/CT imaging after
pre-treatment with two injections of rhTSH. 18F-FDG
will be administered and 18F-FDG PET/CT will be per-
formed 60 minutes post injection. Subsequently, 74 mega-
becquerel (MBq) of 124I is administered intravenously. 124I
PET/CT scans are then performed 24 and 96 hours after
administration of 124I.
Between ‘pre-therapy phase’ and ‘therapy phase’
If either the 18F-FDG PET/CT or the 124I PET/CT shows
metastatic lesions and it is possible to acquire a biopsy from
the lesion, this will be done to correlate histopathologicaled according to local radiation safety regulations; *if available in
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section specimen of the original tumor. If multiple meta-
static lesions are present on either of the scans, a biopsy
will be pursued to acquire from every lesion, but only
if the 124I or FDG uptake differs between the different
lesions. This will be done in easily accessible metastatic
lesions without large risks of complications and/or
discomfort for the subject.
After the pre-therapy phase, subjects will start thyroid
hormone withdrawal 4 weeks prior to 131I therapy. A
low-iodine diet (LID) will be prescribed one week before
the therapy.
Therapy phase
Subjects will undergo 131I therapy with 7400 MBq of 131I
orally. In a subgroup of subjects (in selected centers)
additional 124I PET/CT scans will be performed for dosi-
metric evaluation. Furthermore, the influence of the
method of preparation for the scan, either withdrawal of
thyroid hormone or rhTSH stimulation, will be evaluated.
Seven days after administration of 131I a post-therapy scin-
tigraphy is made, combined with SPECT/CT if available.
Follow-up phase
Six months after therapy both Tg and TSH levels will be
determined after rhTSH administration. If the previous
18F-FDG PET/CT or the 124I PET/CT showed pathological
uptake, that specific PET modality will be repeated. If both
PET techniques were positive during the pre-therapy
phase, both the 18F-FDG PET/CT and the 124I PET/CT
will be repeated.
If another treatment modality, e.g. surgery, external
beam radiotherapy or multikinase inhibitors, is indicated
after the 131I therapy the data of this additional therapy
will be collected as well. If a metastatic lesion is removed
surgically the histopathological specimen will be col-
lected for additional staining and reviewing by an expert
endocrine pathologist.
Additional protocol information
Histopathology thyroidectomy specimen
From every included subject original resection specimens
of the thyroid will be collected and if possible additional
staining will be done. All specimens will be reviewed and
scored by an expert endocrine pathologist.
Histopathology biopsies
If one or more biopsies are acquired from the subjects
between the pre-therapy and therapy phase they will be
stored fresh-frozen and analyzed later.
Review panel
The local nuclear physician will assess all scans and, add-
itionally, an expert review panel consisting of experiencednuclear physicians will assess every scan and every lesion
individually as either positive or negative. Finally, the
expert panel will discuss their disagreements to reach
consensus on every scan and of every lesion in each scan.
Sample size calculation
The power calculation is based on the (conservative) as-
sumption that 40% of patients currently undergo a futile
treatment. With approximately 50 evaluable patients
per year in the Netherlands, we estimate we are able to
include a minimum of 100 patients in 3 years. With a
sample size of exactly 100 evaluable patients, a two-
sided 95.0% confidence interval for a single proportion
using the Pearson-Klopper method for constructing the
confidence interval (exact binomial CI) will extend 10%
from the observed proportion for an expected propor-
tion of 40%.
Recruitment and consent
The patients will be selected for potential participation
by the endocrinologist. After consultation with on whether
the patient is eligible the local principal investigator of the
study the endocrinologist informs the patient. Informed
consent is acquired at least a week later by the local prin-
cipal investigator. See Additional file 1 for a list of partici-
pating centers.
Withdrawal of individual subjects
Subjects of the study can leave the study at any time for
any reason without any consequences. The investigator
can decide to withdraw a subject from the study for ur-
gent medical reasons. For every subject that decides to
withdraw from the study a new subject will be included.
In this way the number of subjects included will not be
changed. If subjects withdraw from the study they will
be offered regular follow-up.
Follow-up of patients
Patients will receive standard follow-up according to the
Dutch guidelines after the subject has completed the
study.
Premature termination of the study
The study relies on 124I PET/CT being predictive for
131I-treatment outcome. When 3 patients have been
encountered with negative 124I PET/CT and positive post-
therapy scintigraphy, the main clinical hypothesis can no
longer be supported and the study will be stopped.
Statistical analysis
Patient demographic data, tumor characteristics and data
derived from the scans will be described in frequency ta-
bles. χ2-tests and trend tests (for ordered scales) will be
used to determine whether a significant reduction in
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the 124I and 18F-FDG PET/CT. More in detail: interpret-
ation of both PET-scans will lead to a positive or nega-
tive treatment proposal. This will be compared with the
actual response on therapy. The definition of a futile
treatment will be a negative post ‘blind’ 131I therapy
scintigraphy. Additionally, accuracy measures such as
sensitivity, specificity, positive and negative predictive
value will be calculated from this data. Multivariate ana-
lysis will be performed whenever appropriate using logistic
regression.
Discussion
Since 124I has become available for PET scanning, the
interest for its use in DTC has been high. More and
more studies addressed its potential use in these pa-
tients. Furthermore, it is well known that during dedif-
ferentiation of DTC, its tumor cells may become FDG
avid and multiple studies have correlated 18F-FDG PET/
CT with aggressiveness of DTC and the loss of iodine
avidity. To our best knowledge no studies however ad-
dressed in a large prospective cohort of patients with re-
current thyroid cancer the additional value of these scan
modalities in the prevention of futile 131I therapies. This
is of great clinical importance as a futile 131I treatment is
costly and not without short- and long-term side effects
and should therefore be restricted to those who will likely
to benefit from this treatment.
Trial status
The Medical the Ethics Board of the Netherlands Cancer
Institute approved the study for all participating centers.
Subsequently, this approval has been checked by all par-
ticipating centers. The study is recruiting patients Since
December 2012. The estimated length of the study is
four years.
Additional file
Additional file 1: List of participating centers.
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